Cellerant Therapeutics, Inc.

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. GSK Becomes Surface Oncology’s Latest B

While the bombs that were triggered by terrorists on 15 April in Boston did not contain radioactive materials, in the wake of that disaster, which demonstrated the ease at which an explosive device co

California biotech Cellerant Therapeutics garnered $36.4 million under an option exercised by the US Biomedical Advanced Research and Development Authority (BARDA) to advance the development of CLT-00

Araim Pharmaceuticals, Cellerant Therapeutics, Neumedicines, RxBio and the University of Arkansas were awarded a total of $56.3 million by the US Biomedical Advanced Research and Development Authority